• In late March 2026, Teva Pharmaceutical Industries reported three biosimilar milestones, including US FDA approval of PONLIMSI (denosumab-adet) as a biosimilar to Prolia for all its osteoporosis-related indications, alongside FDA and EMA acceptance of filings for a proposed Xolair (omalizumab) biosimilar across its full label.
• These advances highlight Teva’s effort to broaden its higher-value biopharmaceutical portfolio, using biosimilars to complement its generics base and support its Pivot to Growth transformation plan.
• We’ll now explore how FDA approval of PONLIMSI and progress on the Xolair biosimilar could influence Teva’s investment narrative and outlook.

Capitalize on the AI infrastructure supercycle with our selection of the 36 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Teva Pharmaceutical Industries Investment Narrative Recap

To stay invested in Teva today, you need to believe its “Pivot to Growth” can gradually rebalance the business toward higher-value branded drugs and biosimilars while managing a still-heavy debt load and a slow-growing generics base. FDA approval of PONLIMSI and progress on the Xolair biosimilar speak directly to that biosimilar pillar, but they do not remove the near term overhang from execution risk in the pipeline and the company’s leverage.

Among the recent announcements, the PONLIMSI approval looks most relevant, because it is a concrete, de-risked asset in Teva’s biosimilar portfolio rather than a filing or early trial. It reinforces the idea that biosimilars could gradually support margins and diversify away from generics, which matters if branded products like AUSTEDO or AJOVY later face pricing pressure or slower growth than hoped.

Yet, against that opportunity, investors should be aware that the biggest near term risk still lies in...

Teva Pharmaceutical Industries' narrative projects $17.9 billion revenue and $2.4 billion earnings by 2029.

Uncover how Teva Pharmaceutical Industries' forecasts yield a $37.82 fair value, a 26% upside to its current price.

Exploring Other Perspectives

Compared with this, the most bearish analysts were assuming only about 1 percent annual revenue growth and earnings of roughly US$1.6 billion by 2028, so they were already cautious on whether late stage neuro and immunology assets like duvakitug and emrusolmin would deliver as hoped, and these new biosimilar milestones may or may not shift that view once fully reflected in their models.

Explore 4 other fair value estimates on Teva Pharmaceutical Industries - why the stock might be worth as much as 96% more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Teva Pharmaceutical Industries research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Teva Pharmaceutical Industries research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Teva Pharmaceutical Industries' overall financial health at a glance.

Seeking Other Investments?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• AI is about to change healthcare. These 36 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Invest in the nuclear renaissance through our list of 93 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.